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CLINICAL THERAPEUTICS

crossm
Inﬂuence of ␤-Lactam Infusion Strategy
on Acute Kidney Injury
Sarah E. Cotner,a W. Cliff Rutter,a,b Donna R. Burgess,a,b Katie L. Wallace,a,b
Craig A. Martin,a,b David S. Burgessb
University of Kentucky HealthCare, Lexington, Kentucky, USAa; University of Kentucky, College of Pharmacy,
Lexington, Kentucky, USAb

Limited literature is available assessing nephrotoxicity with prolonged
␤-lactam infusions. This study compared the incidence of acute kidney injury (AKI)
associated with a prolonged ␤-lactam infusion or an intermittent infusion. This was a
retrospective, matched-cohort study at an academic medical center from July 2006
to September 2015. Adult patients who received piperacillin-tazobactam (TZP),
cefepime (FEP), or meropenem (MEM) for at least 48 h were evaluated. Patients were
excluded for preexisting renal dysfunction or pregnancy. The primary outcome was
difference in incidence of AKI evaluated using the RIFLE (risk, injury, failure, loss, and
end-stage) criteria. Patients in the intermittent group were matched 3:1 to patients
in the prolonged-infusion group based on the following: ␤-lactam agent, age, gender, Charlson comorbidity index, baseline creatinine clearance, hypotension, receipt
of vancomycin, and treatment in an intensive care unit. A total of 2,390 patients
were included in the matched analysis, with 1,700 receiving intermittent infusions
and 690 receiving prolonged infusion. The incidence of AKI was similar in the
prolonged-infusion group to that in the intermittent-infusion group (21.6% versus
18.6%; P ⫽ 0.1). After multivariate regression, prolonged infusion was not associated
with increased odds of AKI (odds ratio [OR], 1.07; 95% conﬁdence interval [95% CI],
0.83 to 1.39). Independent predictors of AKI included TZP therapy, concomitant
nephrotoxins, hypotension, and heart failure. Although AKIs were numerically more
common in patients receiving prolonged ␤-lactam infusions than those receiving intermittent infusions, prolonged infusion was not an independent risk factor for AKI.
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he ␤-Lactam antibiotics are an antimicrobial class with extensive clinical utility and
are the mainstay of treatment in many Gram-positive and Gram-negative infections.
These agents are bactericidal through inhibition of bacterial cell wall synthesis and exhibit
time-dependent killing of microorganisms (1). Thus, the activity of ␤-lactam antibiotics
depends on the free drug concentration time above the MIC of the targeted organism.
␤-Lactams are typically dosed intermittently and infused over 30 to 60 min. Prolonged
␤-lactam infusions are promoted as a strategy to optimize the percentage of the dosing
interval that the concentration of free drug remains above the MIC. Enhancement of
␤-lactam pharmacodynamics is particularly useful in critically ill patients with altered
pharmacokinetics and those who are at risk for resistant pathogens. Prolonged ␤-lactam
infusions are associated with decreased mortality in patients diagnosed with pneumonia, as
well as invasive Pseudomonas aeruginosa infections (2, 3).
While nephrotoxicity is a known adverse effect of ␤-lactam antibiotics, there is a low
reported incidence of nephrotoxicity associated with traditional intermittent dosing.
Mechanisms of nephrotoxicity reported with beta-lactams include primarily acute
interstitial nephritis (AIN) and glomerulonephritis, although acute tubular necrosis
(ATN) has been noted (4, 5). The prolonged-infusion literature available primarily
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FIG 1 Patient selection diagram.

focuses on efﬁcacy rather than safety. Thus, there is limited information available
regarding nephrotoxicity with prolonged infusion; the ␤-lactam evaluated in existing
prolonged-infusion literature is piperacillin-tazobactam (TZP). Lau and colleagues reported drug-related adverse events in their evaluation of TZP administered via a
continuous infusion over 24 h versus intermittent infusion given every 6 h (6). Renal
failure was noted as a treatment-related adverse event in one patient treated with TZP
continuous infusion. McCormick et al. completed a retrospective study of 200 patients
and did not ﬁnd a difference in acute kidney injuries (AKIs) between patients receiving
intermittent TZP infusions versus those receiving extended infusions (11% versus 9%;
P ⫽ 0.637) (7). The literature to date suggests similar rates of nephrotoxicity in patients
receiving TZP and vancomycin (VAN) combination therapy, regardless of TZP infusion
strategy (8, 9). No previous studies have reported the impact of prolonged infusions on
AKI with ␤-lactams other than TZP. Therefore, this study was formulated to evaluate the
incidence of AKIs based on TZP, cefepime (FEP), or meropenem (MEM) infusion strategy.
RESULTS
In total, 2,390 patients of the 18,313 evaluated met criteria to be included in our
matched analysis (Fig. 1), with 1,700 receiving intermittent infusions and 690 receiving
prolonged infusions.
The baseline characteristics of the matched cohort are displayed in Table 1. The
majority of baseline factors were well balanced between the prolonged-infusion and
intermittent-infusion groups, with the exception of exposure to aminoglycosides,
calcineurin inhibitors, intravenous (i.v.) contrast dye, loop diuretics, and vasopressors.
TZP was the most common ␤-lactam utilized, with 37.0% of patients in the prolongedinfusion group and 46.4% in the intermittent-infusion group receiving this antimicrobial. FEP was administered in the prolonged-infusion group to 31.0% of patients and
36.6% in the intermittent-infusion group. More patients in the prolonged-infusion
group received MEM (32.0% versus 16.9%; P ⬍ 0.0001). Length of hospital stay was
signiﬁcantly longer in the prolonged-infusion cohort (median of 12 days [range, 7 to 21
days] versus 10 days [5 to 18 days]; P ⬍ 0.0001).
AKI incidences were similar between the prolonged- and intermittent-infusion
October 2017 Volume 61 Issue 10 e00871-17
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TABLE 1 Baseline patient characteristics of matched cohort
Result for infusion strategyb
Variablea
Age, mean (SD) yr
Male, no. (%)
Caucasian, no. (%)
Charlson comorbidity score, median (IQR)

Prolonged
(n ⴝ 690)
53.47 (17.1)
427 (61.9)
631 (91.4)
3 (1–5)

Intermittent
(n ⴝ 1,700)
53.48 (16.9)
1,028 (60.5)
1,562 (91.9)
3 (1–6)

Baseline CLCR, no. (%)
30–59 ml/min
60–89 ml/min
ⱖ90 ml/min

129 (18.7)
193 (28.0)
368 (53.3)

331 (19.5)
469 (27.6)
900 (52.9)

ICU admission, no. (%)

189 (27.4)

431 (25.3)

0.328

Comorbidities, no. (%)
Diabetes mellitus
Heart failure
Hypertension
Hypotension

159 (23.0)
118 (17.1)
384 (55.6)
428 (62.0)

451 (26.5)
241 (14.2)
905 (53.2)
1,002 (58.9)

0.0855
0.08
0.303
0.177

␤-Lactam received, no. (%)
Piperacillin-tazobactam
Cefepime
Meropenem

255 (37.0)
214 (31.0)
221 (32.0)

789 (46.4)
623 (36.6)
288 (16.9)

Concomitant nephrotoxins, no. (%)
Aminoglycoside
Amphotericin B
ACE inhibitor
ARB
Calcineurin inhibitors
i.v. contrast dye
Loop diuretics
NSAIDs
Vancomycin
Vasopressors

154 (22.3)
13 (1.9)
118 (17.1)
24 (3.5)
91 (13.2)
271 (39.3)
134 (19.4)
33 (4.8)
533 (77.2)
136 (19.7)

226 (13.3)
37 (2.2)
313 (18.4)
57 (3.3)
165 (9.7)
553 (32.5)
233 (13.7)
65 (3.8)
1,327 (78.1)
236 (13.9)

P value
0.982
0.551
0.789
0.518
0.908

⬍0.0001

⬍0.0001
0.768
0.486
0.977
0.0154
0.0019
0.0006
0.338
0.705
0.0005

aAbbreviations:

IQR, interquartile range; CLCR, creatinine clearance; ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blocker; NSAIDs, nonsteroidal anti-inﬂammatory drugs.
bThe values shown represent the number (percentage) of patients unless otherwise indicated.

cohorts (21.6% versus 18.6%; P ⫽ 0.104), with no difference when stratiﬁed by RIFLE
(risk, injury, failure, loss, and end-stage) criteria (Table 2). AKIs were more common
among patients who received TZP (24.9%) compared to those receiving FEP or MEM
(15.9% and 14.1%, respectively; P ⬍ 0.00001). After multiple regression, prolonged
infusion was not associated with increased odds of AKI (OR, 1.07; 95% conﬁdence
interval [CI], 0.83 to 1.39). Several independent predictors of AKI were identiﬁed in the
analysis (Table 3). Concomitant nephrotoxins associated with increased risk of AKI
included aminoglycosides, amphotericin B, calcineurin inhibitors, loop diuretics, vancomycin, and vasopressors. Patients receiving TZP had 1.95 times the odds of AKI (95%

TABLE 2 Incidence of nephrotoxicity by infusion strategy
Result for infusion strategya
Variable
AKI incidence, no. (%)

Prolonged (n ⴝ 690)
149 (21.6)

Intermittent (n ⴝ 1,700)
316 (18.6)

RIFLE criteria, no. (%)
Risk
Injury
Failure

86 (12.5)
39 (5.7)
24 (3.5)

186 (10.9)
74 (4.4)
56 (3.3)

aThe

P value
0.104

values shown represent the number (percentage) of patients.
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TABLE 3 Multivariate regression results postmatchinga
Bivariable regression

Multivariable regression

OR

CI

P value

aOR

CI

P value

1.21

0.97–1.50

0.093

1.07

0.83–1.39

0.584

Age group
18–44 yr (reference)
45–64 yr
65–79 yr
ⱖ80 yr

1.21
1.19
0.80

0.95–1.55
0.89–1.58
0.49–1.28

0.12
0.25
0.376

1.11
1.23
1.10

0.83–1.48
0.85–1.78
0.61–2.00

0.474
0.266
0.745

Male
Caucasian
Charlson comorbidity score

1.06
0.78
1.02

0.86–1.30
0.55–1.11
1.00–1.05

0.603
0.15
0.099

0.70
1.00

0.47–1.03
0.97–1.04

0.069
0.856

Baseline CLCR of:
30–59 ml/min (reference)
60–89 ml/min
ⱖ90 ml/min

0.86
1.33

0.63–1.19
1.02–1.76

0.362
0.04

1.13
2.42

0.78–1.65
1.67–3.50

0.51
⬍0.001

Comorbidities
Diabetes
Heart failure
ICU admission
Hypotension
Hypertension

1.09
2.74
1.35
2.17
1.13

0.87–1.37
2.14–3.50
1.08–1.68
1.73–2.72
0.92–1.38

0.454
⬍0.001
0.009
⬍0.001
0.245

1.78
0.99
1.43

1.31–2.43
0.75–1.29
1.10–1.85

⬍0.001
0.918
0.007

␤-Lactam
Cefepime (reference)
Meropenem
Piperacillin-tazobactam

0.87
1.76

0.64–1.19
1.39–2.22

0.388
⬍0.001

1.04
1.95

0.73–1.48
1.50–2.52

0.831
⬍0.001

Concomitant nephrotoxins
Aminoglycoside
Amphotericin B
ACE inhibitor
ARB
i.v. contrast dye
Calcineurin inhibitor
Loop diuretic
NSAIDs
Vancomycin
Vasopressor

2.41
2.84
1.23
0.94
0.79
2.19
3.75
0.80
2.39
3.34

1.88–3.07
1.57–5.01
0.95–1.59
0.51–1.61
0.55–1.11
1.40–3.34
3.05–4.64
0.59–1.07
1.79–3.24
2.62–4.24

⬍0.001
⬍0.001
0.103
0.828
0.193
⬍0.001
⬍0.001
0.137
⬍0.001
⬍0.001

1.71
2.13
1.04
0.97
0.84
2.13
2.74
0.70
1.60
1.98

1.29–2.27
1.03–4.43
0.76–1.41
0.50–1.88
0.57–1.24
1.27–3.57
2.13–3.53
0.50–0.99
1.16–2.21
1.45–2.72

⬍0.001
0.042
0.825
0.935
0.386
0.004
⬍0.001
0.041
0.004
⬍0.001

Covariate
Treatment group
Intermittent infusion (reference)
Prolonged infusion

aOR,

odds ratio; CI, conﬁdence interval; aOR, adjusted odds ratio; CLCR, creatinine clearance; ICU, intensive
care unit; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; NSAIDs, nonsteroidal
anti-inﬂammatory drugs.

CI, 1.50 to 2.52) compared to those receiving FEP. Patients experiencing hypotension
had 1.43 times the odds of AKI (95% CI, 1.10 to 1.85). Heart failure at baseline was
associated with a 1.78 multiplicative increase in AKI odds (95% CI, 1.31 to 2.43).
DISCUSSION
In this single-center, retrospective matched-cohort study, we compared rates of
nephrotoxicity in patients who received prolonged infusion of ␤-lactams versus those
with intermittent infusion. The incidence of AKI according to RIFLE criteria was 21.6%
with a prolonged-infusion strategy compared to 18.6% with an intermittent-infusion
strategy. Our observed nephrotoxicity rates were higher than the 9 to 11% reported by
McCormick et al. (7). This variance may be explained by differences in patient populations and AKI deﬁnition; while we deﬁned AKI with RIFLE criteria, McCormick and
colleagues deﬁned acute renal injury by an increase in serum creatinine of 0.5 mg/dl
within 24 h or a serum creatinine level of 2 times the patient’s baseline value.
Although the prolonged-infusion group had a numerically higher incidence of
October 2017 Volume 61 Issue 10 e00871-17
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AKI than the intermittent-infusion group, multiple regression analysis revealed that
prolonged infusion was not independently associated with an increased risk of AKI.
Many of the variables that were independent risk factors of AKI in multiple regression analysis are anticipated, including administration of concomitant nephrotoxins,
hypotension, and receipt of TZP. Recent literature continues to suggest that TZP is
associated with a higher incidence of AKI than other intravenous ␤-lactams when used
concomitantly with VAN (10, 11). Burgess and Drew reported that patients receiving
VAN combined with TZP were more likely to develop nephrotoxicity than patients who
received VAN alone (8.1% versus 16.3%; P ⬍ 0.041) (10). In a study by Gomes and
colleagues, the incidence of AKI in patients receiving TZP and VAN was signiﬁcantly
higher than that in patients receiving FEP and VAN (36.4% versus 10.9%; P ⫽ 0.003) in
the matched analysis, and the investigators concluded that the combination of TZP and
VAN was an independent predictor of AKI (11). The concern for AKI induced with use
of TZP and VAN combination therapy raised a new clinical question— does the infusion
strategy of TZP affect the incidence of AKI when used concomitantly with VAN?
Documented nephrotoxicity rates in patients receiving TZP and vancomycin (VAN)
combination therapy are similar, regardless of TZP infusion strategy (8, 9). Results of a
study including 320 patients performed by Karino and colleagues suggest comparable
rates of AKI (32.5% versus 33.1%; P ⫽ 1.0) in the prolonged- and intermittent-infusion
groups, respectively (8). Mousavi et al. had analogous ﬁndings in their study of 280
patients receiving combination TZP and VAN; the rates of nephrotoxicity did not differ
based on TZP infusion strategy (prolonged infusion, 17.9%, versus intermittent, 17.1%;
P ⬎ 0.99) (9). The TZP nephrotoxicity rate in our study is similar to what has been
reported in the literature to date; however, unlike previous studies, not all patients
received vancomycin in combination with a ␤-lactam in our analysis (77.2% in the
prolonged-infusion group versus 78.1% in the intermittent-infusion group). Additionally, no previous studies have reported the impact of prolonged infusion on AKI with
␤-lactams other than TZP.
This study had several limitations, speciﬁcally the single-center, retrospective design.
An attempt to reduce bias and control for confounders was made through propensity
score matching and multiple logistic regression analysis. During the study period, there
was no protocol in place at our institution for use of extended-infusion ␤-lactams. Due
to the retrospective nature of the study, evaluation of nursing compliance with the
prolonged-infusion order was not possible. Additionally, we acknowledge that the
potentials for nephrotoxicity were assumed to be equal among the concomitant
nephrotoxins analyzed. Exclusion of patients with a preexisting need for renal replacement and creatinine clearance (CLCR) of ⬍30 ml/min will limit the generalizability of our
results. Despite these limitations, this study currently provides the largest set of data
available assessing nephrotoxicity of prolonged-infusion ␤-lactams.
In conclusion, prolonged infusion was not independently associated with increased
AKI risk compared to intermittent infusion. The results of this large retrospective study
lessen any concern that the use of prolonged infusion will cause increased incidence of
AKI and suggest it is safe for clinicians to prolong ␤-lactam infusions to optimize
efﬁcacy of treatment in their patients.
MATERIALS AND METHODS
Study design and setting. This retrospective matched-cohort study was conducted at University
of Kentucky HealthCare (UKHC) in Lexington, KY, which is comprised of two hospitals, the Albert B.
Chandler Medical Center and Good Samaritan Hospital. The study was approved by the investigational review board with a waiver of consent. Adult patients admitted from July 2006 to September
2015 who received TZP, FEP, or MEM for at least 48 h were evaluated. Patients were excluded for
preexisting renal dysfunction, cystic ﬁbrosis, or pregnancy. Preexisting renal dysfunction was deﬁned
as the need for renal replacement therapy or creatinine clearance (CLCR) of ⬍30 ml/min at
presentation.
Data source and collection. Clinical data were extracted from the University of Kentucky Center for
Clinical and Translational Science Enterprise Data Trust (EDT). Data stored in the EDT include demographics, ﬁnancial classiﬁcation (Medicare, Medicaid, private insurance), medical diagnoses (International
Classiﬁcation of Diseases 9 [ICD-9]), medical procedures (Current Procedural Terminology [CPT] codes),
laboratory results, vital signs, and visit details (length of stay, medical providers, etc.).
October 2017 Volume 61 Issue 10 e00871-17
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Data collected included demographics, hospital visit data (length of stay, admitting and primary
diagnosis codes), laboratory values and vital signs obtained throughout admission, immunosuppression
status, receipt of concomitant nephrotoxins (listed in Table 1), severity of underlying comorbidity as
deﬁned by the Charlson comorbidity index (12), and mortality information. Baseline creatinine
clearance was calculated with the adjusted Cockcroft-Gault equation from the ﬁrst documented
serum creatinine level measured during admission (13). Concomitant nephrotoxins were deﬁned as
receipt of at least 1 dose of a nephrotoxic agent during or within 24 h of treatment with ␤-lactams.
Hypotension was deﬁned as diagnosis of hypotension by ICD-9 codes, mean arterial pressure of ⬍60
mm Hg, or receipt of vasopressors during or within 24 h of treatment (14). Antibiotic information
obtained included dosing regimen and days of antibiotic therapy, deﬁned as receipt of at least one
dose of antibiotic per day.
Study outcome. The primary objective was to evaluate the incidence of AKI in patients receiving
prolonged infusion ␤-lactam therapy compared to intermittent ␤-lactam therapy deﬁned by the RIFLE
(risk, injury, failure, loss, and end-stage) criteria (15). Prolonged infusion in this study includes both
extended infusions and infusions administered continuously over 24 h. ␤-Lactam infusion strategy was
determined by the individual prescriber. Glomerular ﬁltration rate (GFR) was estimated using the
maximum serum creatinine level between 48 h of initiation of the ␤-lactam regimen through 7 days after
the last dose of antibiotics. The GFR estimation for use in the RIFLE criteria was completed via the
adjusted Cockcroft-Gault equation (13).
Patient matching. Propensity score matching was utilized to reduce potential bias and mimic
randomization. Patients in the intermittent group were matched 3:1 to patients in the prolongedinfusion group based on the logistic regression model with the following variables included: ␤-lactam
agent, age (as a categorical variable: 18 to 44, 45 to 64, 65 to 79, or ⱖ80 years of age), gender, Charlson
comorbidity index, baseline creatinine clearance, hypotension, receipt of vancomycin, and treatment in
the intensive care unit. A greedy, nearest-neighbor matching algorithm with a caliper of 0.2 was utilized
to ensure adequate matches.
Statistical analysis. Descriptive statistics were performed for the study population. Baseline characteristics for each group were compared using a 2-tailed Student’s t test or Wilcoxon rank sum test for
continuous variables and chi-square or Fisher’s exact test for categorical variables. Following propensity
score matching, bivariable logistic regression models were generated to describe relationships between
the variables and outcomes. The ﬁnal multiple regression model was created using covariates associated
with AKI from the bivariable models at a P value of ⬍0.2. Signiﬁcance was deﬁned at an ␣ of 0.05.
Goodness of ﬁt of the multivariate logistic regression was evaluated with the standardized HosmerLemeshow test (16).
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